Logo
x

Search

Subscribe Now

Ono Pharmaceutical

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

  • April 1, 2025
Ono Pharmaceutical Reports the US FDA Approval of Romvimza to Treat Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults

Ono Pharmaceutical Reports the US FDA Approval of Romvimza to Treat Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults

  • February 17, 2025
Ono Pharmaceutical Reports the EMA’s Acceptance of MAA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Reports the EMA’s Acceptance of MAA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor (TGCT)

  • July 19, 2024
ONO Pharmaceutical Reports Acquisition of Deciphera Pharmaceuticals for $2.4B

ONO Pharmaceutical Reports Acquisition of Deciphera Pharmaceuticals for $2.4B

  • April 30, 2024
Ono Pharmaceutical and InveniAI Collaborate to Identify Novel Therapeutic Targets Using Artificial Intelligence (AI) and Machine Learning (ML)

Ono Pharmaceutical and InveniAI Collaborate to Identify Novel Therapeutic Targets Using Artificial Intelligence (AI) and Machine L...

  • February 20, 2024
Ono Pharmaceutical and Shattuck Labs Collaborate to Develop Bifunctional Fusion Proteins for Treating Autoimmune and Inflammatory Diseases

Ono Pharmaceutical and Shattuck Labs Collaborate to Develop Bifunctional Fusion Proteins for Treating Autoimmune and Inflammatory...

  • February 15, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.